Sweden 28 Nov 2017

Patent dispute concerning the use of the gene scissor

A patent dispute about the gene scissor CRISPR/Cas9 is ongoing in the United States and in Europe and is concerned with who will be able to use the technology. The battle is likely to slow the development of medicines and become expensive for companies, according to Swedish Television Science (SVT).

A research team in the United States led by Feng Zhang at the Broad Institute/MIT has obtained a patent for this groundbreaking technology for use in eukaryotic cells, but this decision has been appealed by the researchers Doudna and Charpentier at UC Berkeley who were first to file patent application concerning the general technology. Doudna and Charpentier were recently granted a patent in Europe covering all use of the technology in bacteria, plants and animals as well as humans, however the grant of the patent has been opposed already. The patent dispute may become long and bitter. According to an article in Science, this battle is likely to slow down the innovation within the field.

The technology has a broad potential and can become a great commercial and economic success and be important for the development of amongst other new treatments for genetic diseases. There is a risk that, with overlapping patents in both the US and Europe, those who want to use the technology will have to pay licenses to both parties.

In the article, our patent consultant Joanna Applequist comments on the ability of companies to utilize the technology from a patent perspective. You can read the article, including Joannas comments, here (in Swedish)

                                                –  o  –

This cutting edge technology, so-called CRIPSR/Cas9, means that you can induce a break in the DNA strand at a desired location, e.g. to turn off the expression of a gene. A targeting RNA molecule is designed to recognize a desired site in the genome, the RNA molecule guides the enzyme Cas9 to this site, and Cas9 cuts the DNA strand right there.

Other news

  • Worldwide 03 Apr 2018

    One of the Crispr/Cas9 patents is revoked

    Read more

  • Stockholm 28 Mar 2018

    Pictures from INTA Pre-Annual Meeting – T...

    Read more

  • Europe 28 Mar 2018

    Patent applications at the EPO increased by 3.9...

    Read more

Top

Contact us

Countries & Contacts.

  • Jordglob

    Stockholm

    Headquarter

    Groth & Co KB
    Box 6107
    SE-102 32 STOCKHOLM

    Visiting address:
    Birger Jarlsgatan 57 B, 113 56 Stockholm
    SWEDEN
    Telephone: +46 8 729 91 00
    Email: info@groth.eu
    Fax: +46 8 31 67 67

    Show on map

  • Jordglob

    Alicante

    Groth & Co KB
    Avda. De Aguilera 19-1 B
    E-03007 ALICANTE
    SPAIN
    Telephone: +34 96 592 04 55
    Email: info@groth.eu
    Fax: +34 96 592 05 03

    Show on map

  • Jordglob

    Munich

    Groth GmbH
    Rosenkavalierplatz 4
    D-81925 MUNICH
    GERMANY
    Telephone: +49 89 982 952 63
    Email: info@groth.eu
    Fax: +49 89 982 952 65

    Show on map

  • Jordglob

    Shanghai

    Groth & Co KB
    378 WuKang Road, Office 303
    200031 SHANGHAI
    CHINA
    Telephone: +86 1361 180 4064
    Email: info@groth.eu

    Show on map